SLC19A3

Across TCGA pan-cancer cohorts, SLC19A3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC19A3 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SLC19A3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SLC19A3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, LSCC, and GBM are the cancer types where SLC19A3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.964	0.318	.017	18	view →
LSCC	DFS	Median	All	0.174	0.805	.017	3	view →
GBM	OS	Median	All	0.506	0.928	.026	3	view →
LUAD	OS	Quartile	II,III,IV	0.306	0.554	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC19A3–CCRCC (OS)

Open the CCRCC breakdown →